Skip to content
DataLookout
Menu

AbbVie clinical trial pipeline

Get alerts when AbbVie's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-08

What changed in the last 30 days

39 trials changed in the last 30 days: 1 stopped, 7 with notable changes, 31 with minor changes only.

  1. Minor: Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space · and Without Diabetic Retinopathy Trial status changed: Enrolling by Invitation → Active, Not Recruiting AbbViePhase 2 NCT05296447
  2. Minor: How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants Trial completed AbbViePhase 1 NCT07649954
  3. Minor: ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics · Obesity Enrollment closed, study ongoing AbbViePhase 1 NCT07291232
  4. Minor: Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA · Moderate to Severe Upper Facial Lines Trial sites expanded: 1 → 21 locations AbbViePhase 2 NCT07871513
  5. Minor: Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body · B-Cell Malignancies Trial arms changed: 4 → 1 AbbViePhase 1 NCT05753501
  6. Minor: Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants · Glabellar Lines Enrollment closed, study ongoing AbbViePhase 1 NCT07756580
  7. Minor: LEGACY · Registry of Humira® (Adalimumab) · Moderately to Severely Active Ulcerative Colitis (UC) Trial completed AbbVieNot specified NCT01848561
  8. Notable: Food Effect Study of ABBV-7828 in Healthy Adults Recruitment opened AbbViePhase 1 NCT07856706
  9. Minor: NAAVIGATE · Surabgene Lomparvovec Administered in the Suprachoroidal Space · Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema Trial sites expanded: 37 → 40 locations AbbViePhase 2/3 NCT07592273
  10. Notable: AURORA · MEDI0618 Compared to Placebo · Episodic Migraine Primary endpoint(s) modified AbbViePhase 2 NCT06602479
  11. Minor: KEEPsAKE2 · Risankizumab to Placebo · Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) Sponsor refiled this as active, not recruiting (was completed) AbbViePhase 3 NCT03671148
  12. Minor: Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor · Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations Trial sites expanded: 124 → 127 locations AbbViePhase 1/2 NCT06772623
  13. Minor: ABBV-295 · Obesity or Overweight With Weight-Related Comorbidities Trial sites expanded: 61 → 64 locations AbbViePhase 2 NCT07752979
  14. Minor: Upadacitinib · Alopecia Areata Trial sites expanded: 9 → 13 locations AbbViePhase 3 NCT07772492
  15. Minor: AGN-151607-DP to Assess Adverse Events and Change in Disease Activity · Upper Limb Essential Tremor Trial sites expanded: 3 → 20 locations AbbViePhase 2 NCT07673107
  16. Stopped: Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies · Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Trial terminated AbbViePhase 1 NCT06487559
  17. Notable: Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants Recruitment opened AbbViePhase 3 NCT07756645
  18. Minor: Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec · Neovascular Age-Related Macular Degeneration (nAMD) Trial sites expanded: 133 → 136 locations AbbViePhase 3 NCT07007065
  19. Minor: MIGHTY · How Risankizumab Works in Young · Ulcerative Colitis Trial sites expanded: 68 → 71 locations AbbViePhase 3 NCT07071519
  20. Minor: Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine · Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Trial sites expanded: 70 → 73 locations AbbViePhase 2 NCT06890338
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-10-29 NCT07904754 Platform Study of Targeted Therapies for Adults With Moderately to Severely Active… Phase 2 Not Yet Recruiting
2026-10-27 NCT07896421 Real-World Study of Mirvetuximab Soravtansine in Adult Participants With… Recruiting
2026-10-27 NCT07896434 A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young… Phase 3 Not Yet Recruiting
2026-10-26 NCT07895043 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV)… Phase 2 Not Yet Recruiting
2026-10-26 NCT07895056 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV)… Phase 2 Not Yet Recruiting
2026-10-19 NCT07880756 Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin… Phase 3 Recruiting
2026-10-13 NCT07871513 A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and… Phase 2 Recruiting

Active trials by phase

Phase 1
50
Phase 1/2
10
Phase 2
52
Phase 2/3
10
Phase 3
63
Phase 4
4
Not charted: 50 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 51

Get alerts when AbbVie's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free